FORMULARY DECISION
Tocilizumab : Tocilizumab
TA375 (SMC 774/12) : For the treatment of monotherapy in rheumatoid arthritis (RA) when biologic combination with methotrexate (MTX) is inappropriate [e.g. due to intolerance to MTX].
Search Results
All Content Formulary Only Other ContentWe have found 17 results when searching "Tocilizumab"
FORMULARY DECISION
Tocilizumab : Tocilizumab
TA373 (SMC 930/13) : Tocilizumab in combination with methotrexate is indicated for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthriti...
FORMULARY DECISION
Tocilizumab : Tocilizumab
982/14 : In combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have either responded inadequately to, or who were intole...
FORMULARY DECISION
Tocilizumab : RoActemra
1020/14 : Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
FORMULARY DECISION
Tocilizumab : RoActemra
1201/16 : Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
FORMULARY DECISION
Tocilizumab : Tocilizumab
SMC2014 : For the treatment of Giant Cell Arteritis (GCA) in adult patients.
FORMULARY DECISION
Tocilizumab : Tocilizumab
SMC2552 : Treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. Refer to local guidelines